Product Description: Dapagliflozin-d4 (BMS-512148-d4) is deuterium labeled Dapagliflozin. Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine[1]. Dapagliflozin induces HIF1 expression and attenuates renal IR injury[2].
Applications: Metabolism-sugar/lipid metabolism
Formula: C21H21D4ClO6
References: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216./[2]Pelissier T, et al. The orofacial capsaicin test in rats: effects of different capsaicin concentrations and morphine. Pain. 2002 Mar;96(1-2):81-7.
CAS Number: 1224234-25-6
Molecular Weight: 412.90
Research Area: Metabolic Disease;Cancer
Target: Isotope-Labeled Compounds;SGLT
Deutsch
English
